BRCA2-positive lung adenocarcinoma treated with olaparib: A case report

A 66-year-old woman was found to have abnormal shadows on a chest radiograph at a previous hospital 4 years ago, which led to a diagnosis of lung adenocarcinoma, cT2aN1M1b stage IVA. First-line treatment included carboplatin and paclitaxel plus thoracic radiotherapy and stereotactic radiation therap...

Full description

Saved in:
Bibliographic Details
Published in:Respirology case reports 2024, Vol.12 (3), p.e01317-e01317
Main Authors: Motohashi, Takumi, Isobe, Kazutoshi, Yoshizawa, Takahiro, Usui, Yusuke, Shimizu, Hiroshige, Sekiya, Muneyuki, Miyoshi, Shion, Nakamura, Yasuhiko, Urabe, Naohisa, Sakamoto, Susumu, Homma, Sakae, Sadamoto, Sota, Tochigi, Naobumi, Kishi, Kazuma
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 66-year-old woman was found to have abnormal shadows on a chest radiograph at a previous hospital 4 years ago, which led to a diagnosis of lung adenocarcinoma, cT2aN1M1b stage IVA. First-line treatment included carboplatin and paclitaxel plus thoracic radiotherapy and stereotactic radiation therapy for brain metastases. The patient later underwent second-line pemetrexed treatment, followed by third-line nivolumab, fourth-line docetaxel and bevacizumab, fifth-line tegafur-gimeracil-oteracil, and sixth-line gemcitabine. Two years ago, after observing an increase in the primary lesion and carcinoembryonic antigen levels (104.0 ng/mL), a computed tomography-guided biopsy was performed from the primary site of lung cancer. A cancer genomic profiling test (FoundationOne® CDx cancer genome profile) revealed a breast cancer susceptibility (BRCA) 2 gene mutation. Therefore, she started taking olaparib. The treatment led to stable disease for approximately 2 years.
ISSN:2051-3380
2051-3380
DOI:10.1002/rcr2.1317